Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346603 · ClinicalTrials.gov registry record
Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs
A clinical trial, sponsored by Olive View-UCLA Education & Research Institute.
- Completed
- Registry status
- 801
- Enrollment target
NCT03346603 is a clinical trial that has completed, run by Olive View-UCLA Education & Research Institute. The registered enrollment target is 801 participants.
The verdict
NCT03346603 has completed, sponsored by Olive View-UCLA Education & Research Institute.
- COMPLETED
- Registry status
- 801 participants
- Enrollment target
Study Summary
Between 2013-2014, our study network of U.S. emergency departments, EMERGEncy ID NET, found that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in uncomplicated and 19.9% in complicated. ESBL-producing Enterobacteriaceae were found in 7.7% of all cases, 2.6% in uncomplicated and 12.2% in complicated. More recently, Enterobactericeae and gram-negative non fermenting bacteria have started to show resistance to carbapenems (CREs and CR-NF). Patients hospitalized with UTI and urosepsis represent a higher risk population for infections due to multi-drug resistant bacteria and experience serious adverse outcomes, including death. EMERGEncy ID NET will conduct a study to determine the prevalence of ESBL-producing, CREs and CR-NFs among this high risk population of patients admitted for UTI from U.S. emergency departments.
Interventions
- OTHER urine culture and susceptibility testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 801 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03346603
The ClinicalTrials.gov registry entry for NCT03346603 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 801 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Olive View-UCLA Education & Research Institute, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which urine culture and susceptibility testing is the first listed.
NCT03346603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03346603 about?
NCT03346603 is a clinical study titled "Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs". Between 2013-2014, our study network of U.S. emergency departments, EMERGEncy ID NET, found that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in uncomplicated and 19.9% in complicated. ESBL-producing Enterobacteriaceae were found in 7.7% of all cases, 2.6% in unco...
What is the current status of trial NCT03346603?
This trial is currently completed. The enrollment target is 801 participants. The study started on 2018-02-08. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03346603?
The interventions under investigation include: urine culture and susceptibility testing (OTHER).
Who is sponsoring clinical trial NCT03346603?
This trial is sponsored by Olive View-UCLA Education & Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.